NERV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 09:30):

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases...

Stats
Today's Volume	616.00
Average Volume	121 574
Market Cap	17.48M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-1.010 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0.0350 (1.40%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-04	Luthringer Remy	Buy	100 450	Employee Stock Option (right to buy)
2023-10-04	Race Geoff	Buy	87 050	Employee Stock Option (right to buy)
2023-10-04	Ahlholm Frederick W	Buy	42 850	Employee Stock Option (right to buy)
2023-09-27	Hasler Hans Peter	Buy	12 500	Stock Option (right to buy)
2023-09-27	Van Heek G Jan	Buy	12 500	Stock Option (right to buy)

INSIDER POWER
34.36
Last 97 transactions
Buy: 4 702 257 \| Sell: 460 450

Minerva Neurosciences Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Minerva Neurosciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-30 982.00 (0.00 %)
EPS:	$-4.61

Q4	2023
Revenue:	$0
Gross Profit:	$-7 746.00 (0.00 %)
EPS:	$-1.190

Q3	2023
Revenue:	$0
Gross Profit:	$-7 745.00 (0.00 %)
EPS:	$-1.030

Q2	2023
Revenue:	$0
Gross Profit:	$-7 746.00 (0.00 %)
EPS:	$-1.120

Financial Reports:

No articles found.

Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.